Skip to content

Clinical Trial on the Effect of Autologous Oral Mucosal Epithelial Sheet Transplantation

An Investigator-initiated Trial (IIT) on the Effect of Autologous Oral Mucosal Epithelial Sheet Transplantation in Corneal Limbal Deficiency Patients

Status
AVAILABLE
Phases
Unknown
Study type
Expanded Access
Source
ClinicalTrials.gov
Registry ID
NCT02149732
Enrollment
Unknown
Registered
2014-05-29
Start date
2014-05-31
Completion date
2016-12-31
Last updated
2016-04-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chemical Burn, Limbal Stem Cell Deficiency, Ocular Cicatricial Pemphigoid, Stevens-johnson Syndrome

Keywords

Limbal stem cell deficiency, Cultivated oral mucosal cell sheet transplantation, Ocular surface reconstruction

Brief summary

To investigate the effect of ocular surface reconstruction and assess the safety in cultivated oral mucosal epithelial cell sheet transplantation (COMET) regarding patients with cicatricial change of ocular surface.

Detailed description

Interventional study for treatment of patients with cicatricial change of ocular surface. Single Group: (Limbal stem cell deficiency group) Treatment: After cultivating autologous Oral mucosal epithelial cell sheet, the sheet will be transplanted to the ocular surface of the patients Inclusion criteria 1. patient with eye which has limbal stem cell deficiency and conjunctivalization of cornea 2. patient who shows no improvement after limbal tissue or amniotic membrane transplantation, or who has difficulty in receiving long-term immunosuppressive treatment 3. patient who agree this clinical trial 4. patient with the eyes in which best corrected visual acuity is less than counting finger 5. patient who is older than sixteen year old Exclusion criteria 1. patient who has relevant corneal transparency 2. patient who is on the pregnancy or has a plan of pregnancy within 1 year 3. patient who has corneal infection 4. patient who has diagnosis of HBV, HCV, HIV, syphilis 5. patinet who has past medial history of antinal, myocardial infarction, heart failure, arrhythmia, brain stroke, cerebrovascular disease 6. patient who has malignancy 7. patient who shows hypersensitivity to bovine protein. Primary outcome Epithelization of corneal surface (6 months after cell sheet transplantation) Secondary outcome Visual acuity (6 months after cell sheet transplantation)

Interventions

BIOLOGICALcultivated oral mucosal epithelial sheet transplantation

Autologous cultivated oral mucosal epithelial cell sheet transplantation using oral mucosal adult stem cells in the patients with intractable corneal limbal deficiency

Sponsors

Ministry of Health & Welfare, Korea
CollaboratorOTHER_GOV
Seoul National University Hospital
Lead SponsorOTHER

Eligibility

Sex/Gender
ALL
Age
16 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. patient with eye which has limbal stem cell deficiency and conjunctivalization of cornea 2. patient who shows no improvement after limbal tissue or amniotic membrane transplantation, or who has difficulty in receiving long-term immunosuppressive treatment 3. patient who agree this clinical trial 4. patient with the eyes in which best corrected visual acuity is less than counting finger 5. patient who is older than sixteen year old

Exclusion criteria

1. patient who has relevant corneal transparency 2. patient who is on the pregnancy or has a plan of pregnancy within 1 year 3. patient who has corneal infection 4. patient who has diagnosis of HBV, HCV, HIV, syphilis 5. patinet who has past medial history of antinal, myocardial infarction, heart failure, arrhythmia, brain stroke, cerebrovascular disease 6. patient who has malignancy 7. patient who shows hypersensitivity to bovine protein.

Countries

South Korea

Contacts

Primary ContactMee Kum Kim, MD, PhD
kmk9@snu.ac.kr82-10-6277-0798
Backup ContactYu Jeong Kim, MD
21cnasa@naver.com82-10-2559-1377

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 8, 2026